Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib

JAAD Case Rep. 2023 Apr 24:37:119-122. doi: 10.1016/j.jdcr.2023.04.007. eCollection 2023 Jul.

Authors

Sara Saheb Kashaf¹, Lucy A Godley², Angad Chadha³, Jason B Waldinger^{1

4}

Affiliations

¹ Pritzker School of Medicine, the University of Chicago, Chicago, Illinois.
² Section of Hematology/Oncology, Department of Medicine and Human Genetics, the University of Chicago, Chicago, Illinois.
³ Section of Dermatology, Department of Medicine, the University of Chicago, Chicago, Illinois.
⁴ Division of Dermatology, Department of Medicine, NorthShore University & Health System, Evanston, Illinois.

No abstract available

Keywords: alopecia; chronic myeloproliferative neoplasm; germline SDHC mutation; ripretinib; systemic mastocytosis.

Publication types

Case Reports

Grants and funding

T32 HD007009/HD/NICHD NIH HHS/United States